Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Relugolix demonstrated comparable effectiveness to degarelix in achieving 12-month castration rates (Relative Risk (RR) 1.09, 95% CrI: 0.95-1.23), with subgroup analysis showing that degarelix at 480 mg was associated with a significantly lower castration rate (RR 0.46, 95% CrI: 0.07-0.92).
• In prostate cancer patients, relugolix ranked as the best treatment option among Catechol-O-Methyltransferase (COMT) inhibitors for increasing total On-State (ON)-time, with a significant reduction in Off-State (OFF)-time (49.91 min, 95% Confidence Interval (CI): -71.39 to -28.43), and a notable levodopa dose reduction compared to placebo.
• Relugolix and degarelix were associated with similar rates of all adverse events (AEs) (RR 0.99, 95% CrI: 0.6-1.6 for relugolix; RR (relative risk) 1.1, 95% CrI: 0.75-1.35 for degarelix) and serious adverse events (SAEs) (RR 0.72, 95% CrI: 0.4-1.3 for relugolix; RR 1.05, 95% CrI: 0.42-2.6 for degarelix).
• Relugolix demonstrated a lower risk of cardiovascular events (RR 0.44, 95% CrI: 0.16-1.2) compared to GnRH agonists, with no injection site reactions due to its oral formulation, a notable difference from degarelix, which can cause injection site reactions.
• The studies primarily focused on men with advanced prostate cancer. Both relugolix and degarelix demonstrated comparable effectiveness overall, with specific attention to improved cardiovascular safety in these populations when compared to GnRH agonists.